Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial

  title={Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial},
  author={Kai C. Wollert and Gerd Peter Meyer and Joachim Lotz and Stefanie Ringes Lichtenberg and Peter Lippolt and Christiane Breidenbach and Stephanie Fichtner and Thomas Korte and Burkhard Hornig and Diethelm Messinger and Lubomir Arseniev and Bernd Hertenstein and Arnold Ganser and Helmut Drexler},
  journal={The Lancet},

Figures and Tables from this paper

Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial.

A single intracoronary application of BMCs does not promote a sustained improvement of LVEF in STEMI patients with relatively preserved systolic function, and it is conceivable that a subgroup of patients with more transmural infarcts may derive a sustained benefit from BMC therapy.

Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: a meta-analysis

Considering the increase in LVEF during follow‐up, transplantation of BMC may be a safe and beneficial procedure to support treatment of AMI and further efforts aiming at large‐scale, double‐blind, randomized and placebo‐controlled multi‐center trials in conjunction with better definition of patients, which benefit from BMC infusion, appear to be warranted.

Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction.

A randomized, controlled trial found no effects of intracoronary injection of autologous mononuclear BMC on global left ventricular function.

Intracoronary Bone Marrow Cell Transfer After Myocardial Infarction: Eighteen Months’ Follow-Up Data From the Randomized, Controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) Trial

In this study, a single dose of intracoronary BMCs did not provide long-term benefit on LV systolic function after AMI compared with a randomized control group; however, the study suggests an acceleration of LV ejection fraction recovery after AMi by BMC therapy.

Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial

It is indicated that intracoronary transfer of autologous BMCs is a safe, promising, and novel approach to further improving systolic function in patients with successful reperfusion after acute myocardial infarction.

Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Intracoronary administration of BMC is associated with improved recovery of left ventricular contractile function in patients with acute myocardial infarction and large-scale studies are warranted to examine the potential effects of progenitor-cell administration on morbidity and mortality.

Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial

The BOOST-2 trial does not support the use of nucleated BMCs in patients with STEMI and moderately reduced LVEF treated according to current standards of early PCI and drug therapy.

Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial.

Intracoronary autologous BMC administration to patients with decreased LVEF after AMI was associated with improvement of myocardial viability in multivariate-but not in univariate-analysis, and a large multicentre international trial is warranted.

Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans.

Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial.

Intracoronary autologous BMC transfer improves echocardiographic parameters of diastolic function in patients after AMI.



Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans

These results demonstrate for the first time that selective intracoronary transplantation of autologous, mononuclear BMCs is safe and seems to be effective under clinical conditions.

Bone marrow cells regenerate infarcted myocardium

It is indicated that locally delivered bone marrow cells can generate de novo myocardium, ameliorating the outcome of coronary artery disease.

Adult stem cell therapy in perspective.

Available information about cardiovascular stem cell therapy is reviewed, early experience in this new field is shared, and future directions are speculated about about future directions.

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

Stent implantation (with or without abciximab therapy) should be considered the routine reperfusion strategy in experienced centers and when used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further improve outcomes.

Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts

Results indicate that haematopoietic stem cells do not readily acquire a cardiac phenotype, and raise a cautionary note for clinical studies of infarct repair.

Bone marrow-Derived Cells Do Not Incorporate Into the Adult Growing Vasculature

The findings suggest that in the adult organism, bone marrow-Derived cells do not promote vascular growth by incorporating into vessel walls but may function as supporting cells.